Literature DB >> 1373187

Rapid acinar to ductal transdifferentiation in cultured human exocrine pancreas.

P A Hall1, N R Lemoine.   

Abstract

Experiments have been performed to define conditions for the primary culture of human exocrine pancreas, as a first step towards molecular reconstruction experiments of pancreatic neoplasia. Normal human exocrine pancreas was digested using collagenase and dispase and the resulting cellular aggregates were cultured in vitro. The phenotype of the digested pancreatic cells was almost exclusively acinar (amylase-positive, keratin 19 and mucin antigens-negative), yet within 4 days of culture the cells had taken on a ductal phenotype (amylase-negative, keratin 19 and mucin antigens-positive). The kinetics of these observations exclude the possibility of overgrowth of the acinar population by a ductal sub-population, and selective adherence is excluded by examination of those cells that do not adhere, which are representative of the initiating population. We interpret these data as indicating that, under the conditions of culture, the acinar cell phenotype is not stable and can transdifferentiate to a ductal phenotype. Taken together with recent data from transgenic animals, this in vitro observation has possible implications for our view of the pathogenesis of pancreatic neoplasia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373187     DOI: 10.1002/path.1711660203

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  46 in total

1.  Determination of cell proliferation.

Authors:  D M Barnes; C E Gillett
Journal:  Clin Mol Pathol       Date:  1995-02

2.  Pancreatic acinar cells produce, release, and respond to tumor necrosis factor-alpha. Role in regulating cell death and pancreatitis.

Authors:  A S Gukovskaya; I Gukovsky; V Zaninovic; M Song; D Sandoval; S Gukovsky; S J Pandol
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

3.  In vitro models of pancreatic cancer for translational oncology research.

Authors:  Georg Feldmann; Sherri Rauenzahn; Anirban Maitra
Journal:  Expert Opin Drug Discov       Date:  2009-04-01       Impact factor: 6.098

Review 4.  Stem cell therapy for type 1 diabetes mellitus.

Authors:  Cristina Aguayo-Mazzucato; Susan Bonner-Weir
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

5.  Expression of cholecystokinin-2/gastrin receptor in the murine pancreas modulates cell adhesion and cell differentiation in vivo.

Authors:  Christiane Bierkamp; Stéphanie Bonhoure; Anne Mathieu; Pascal Clerc; Daniel Fourmy; Lucien Pradayrol; Catherine Seva; Marlène Dufresne
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

6.  Hypothermic storage and preservation of human pancreatic acinar tissue.

Authors:  Margaret Coutts; Steven Hinton; Jie Zheng; David W Scharp
Journal:  In Vitro Cell Dev Biol Anim       Date:  2007-01       Impact factor: 2.416

Review 7.  Pancreatic cancer - a continuing challenge in oncology.

Authors:  Attila Zalatnai
Journal:  Pathol Oncol Res       Date:  2003-12-22       Impact factor: 3.201

8.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

9.  Trypsinogen expression by two human pancreatic cell lines CFPAC-1 and CAPAN-1. Modulation during spontaneous and induced cell growth.

Authors:  B Miszczuk-Jamska; M Merten; W Renaud; O Guy-Crotte; C Figarella
Journal:  Int J Pancreatol       Date:  1994-08

10.  Paracrine Secretion of Transforming Growth Factor β by Ductal Cells Promotes Acinar-to-Ductal Metaplasia in Cultured Human Exocrine Pancreas Tissues.

Authors:  Naoki Akanuma; Jun Liu; Geou-Yarh Liou; Xue Yin; Kaitlyn R Bejar; Chengyang Liu; Lu-Zhe Sun; Peter Storz; Pei Wang
Journal:  Pancreas       Date:  2017-10       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.